Recombinant Activated Factor VII: A Solution to Refractory Haemorrhage in Vascular Surgery?

European Journal of Vascular and Endovascular Surgery

Volumn 35, Issue 2, 2008, Pages 145-152

  Warren, O J ^a   Alcock, E M H ^a   Choong, A M T L ^a,b   Leff, D R ^a   Van Herzeele, I ^a,b   Darzi, A W ^a   Athanasiou, T ^a   Cheshire, N J W ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Aneurysm; Haemorrhage; Recombinant FVIIa; Surgery; Vascular Diseases

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AORTA SURGERY; ARTERY THROMBOSIS; BLEEDING; BLOOD TRANSFUSION; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTIVE SURGERY; ENDOVASCULAR SURGERY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; VASCULAR SURGERY;

ADULT; AGED; AGED, 80 AND OVER; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE TRANSFUSION; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RESEARCH DESIGN; THROMBOSIS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 38549099164     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2007.08.018     Document Type: Review

References (57)

1. Cohen J.R., Angus L., Asher A., Chang J.B., and Wise L. Disseminated intravascular coagulation as a result of supraceliac clamping: implications for thoracoabdominal aneurysm repair. Ann Vasc Surg 1 5 (1987) 552-557
2. Jelenska M.M., Szmidt J., Bojakowski K., Grzela T., and Palester-Chlebowczyk M. Compensated activation of coagulation in patients with abdominal aortic aneurysm: effects of heparin treatment prior to elective surgery. Thromb Haemost 92 5 (2004) 997-1002
3. Halpern V.J., Kline R.G., D'Angelo A.J., and Cohen J.R. Factors that affect the survival rate of patients with ruptured abdominal aortic aneurysms. J Vasc Surg 26 6 (1997) 939-945 [discussion 945-938]
4. Sultan S., Manecksha R., O'Sullivan J., Hynes N., Quill D., and Courtney D. Survival of ruptured abdominal aortic aneurysms in the west of Ireland: do prognostic indicators of outcome exist?. Vasc Endovascular Surg 38 1 (2004) 43-49
5. Sedrakyan A., Wu A., Sedrakyan G., Diener-West M., Tranquilli M., and Elefteriades J. Aprotinin use in thoracic aortic surgery: safety and outcomes. J Thorac Cardiovasc Surg 132 4 (2006) 909-917
6. Huber T.S., Carlton L.C., Irwin P.B., Flug R.R., Harward T.R., Flynn T.C., et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction. J Surg Res 67 1 (1997) 14-20
7. Milne A.A., Drummond G.B., Paterson D.A., Murphy W.G., and Ruckley C.V. Disseminated intravascular coagulation after aortic aneurysm repair, intraoperative salvage autotransfusion, and aprotinin. Lancet 344 8920 (1994) 470-471
8. Hedner U., Glazer S., Pingel K., Alberts K.A., Blomback M., Schulman S., et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 2 8621 (1988) 1193
9. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 26 4 (2000) 363-366
10. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., and Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 3 (2006) 293-298
11. Warren O., Mandal K., Hadjianastassiou V., Knowlton L., Panesar S., John K., et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 83 2 (2007) 707-714
12. Friederich P.W., Henny C.P., Messelink E.J., Geerdink M.G., Keller T., Kurth K.H., et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361 9353 (2003) 201-205
13. Raobaikady R., Redman J., Ball J.A., Maloney G., and Grounds R.M. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 94 5 (2005) 586-591
14. Tawfick W.A., Tawfik S., Hynes N., Mahendran B., and Sultan S. Critical bleeding in vascular surgery: expanding the indication of recombinant activated factor VII. Vascular 14 1 (2006) 32-37
15. Cheng C.A., and Ho A.M. Use of recombinant activated factor VII after axillofemoral bypass grafting. Anaesth Intensive Care 34 3 (2006) 375-378
16. Raux M., Chiche L., Vanhille E., and Riou B. Recombinant activated factor vii to control massive post operative bleeding after septic aortobifemoral grafting. Eur J Anaesthesiol 22 10 (2005) 805-807
17. Liem A.K., Biesma D.H., Ernst S.M., and Schepens A.A. Recombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms. Thromb Haemost 82 1 (1999) 150-151
18. Wahlgren C.M., and Swedenborg J. The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 26 2 (2003) 221-222
19. Benharash P., Bongard F., and Putnam B. Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients. Am Surg 71 9 (2005) 776-780
20. Laffan M., O'Connell N.M., Perry D.J., Hodgson A.J., O'Shaughnessy D., and Smith O.P. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul Fibrinolysis 14 1 (2003) S35-S38
21. O'Connell N.M., Perry D.J., Hodgson A.J., O'Shaughnessy D.F., Laffan M.A., and Smith O.P. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 43 12 (2003) 1711-1716
22. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 22 4 (2002) 539-548
23. Jude B., Zawadzki C., Susen S., and Corseaux D. Relevance of tissue factor in cardiovascular disease. Arch Mal Coeur Vaiss 98 6 (2005) 667-671
24. Ardissino D., Merlini P.A., Ariens R., Coppola R., Bramucci E., and Mannucci P.M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349 9054 (1997) 769-771
25. Nijziel M., van Oerle R., van 't Veer C., van Pampus E., Lindhout T., and Hamulyak K. Tissue factor activity in human monocytes is regulated by plasma: implications for the high and low responder phenomenon. Br J Haematol 112 1 (2001) 98-104
26. Maugeri N., Brambilla M., Camera M., Carbone A., Tremoli E., Donati M.B., et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost 4 6 (2006) 1323-1330
27. Osterud B., and Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 32 1 (2006) 11-23
28. Khan M.M., Hattori T., Niewiarowski S., Edmunds Jr. L.H., and Colman R.W. Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII. Thromb Haemost 95 3 (2006) 462-468
29. Diamant M., Nieuwland R., Pablo R.F., Sturk A., Smit J.W., and Radder J.K. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 106 19 (2002) 2442-2447
30. Giesen P.L., Rauch U., Bohrmann B., Kling D., Roque M., Fallon J.T., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96 5 (1999) 2311-2315
31. Santucci R.A., Erlich J., Labriola J., Wilson M., Kao K.J., Kickler T.S., et al. Measurement of tissue factor activity in whole blood. Thromb Haemost 83 3 (2000) 445-454
32. Butenas S., and Mann K.G. Active tissue factor in blood?. Nat Med 10 11 (2004) 1155-1156 [author reply 1156]
33. Hedner U., and Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 1 2 (2003) 112-119
34. Butenas S., Brummel K.E., Paradis S.G., and Mann K.G. Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia. Arterioscler Thromb Vasc Biol 23 1 (2003) 123-129
35. ten Cate H., Bauer K.A., Levi M., Edgington T.S., Sublett R.D., Barzegar S., et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 92 3 (1993) 1207-1212
36. Lisman T., and De Groot P.G. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 1 6 (2003) 1138-1139
37. Bom V.J., and Bertina R.M. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 265 2 (1990) 327-336
38. Monroe D.M., Hoffman M., Oliver J.A., and Roberts H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99 3 (1997) 542-547
39. Hoffman M., Monroe D.M., and Roberts H.R. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 83 1 (1994) 38-42
40. Gerotziafas G.T., Chakroun T., Depasse F., Arzoglou P., Samama M.M., and Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 91 5 (2004) 977-985
41. Manning B.J., Hynes N., Courtney D.F., and Sultan S. Recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery. Eur J Vasc Endovasc Surg 30 5 (2005) 525-527
42. Pugh R.J., Wenstone R., Martlew V.J., and Marx G. Use of recombinant factor VIIa for major haemorrhage. Eur J Anaesthesiol 22 7 (2005) 548-550
43. Aggarwal A., Malkovska V., Catlett J.P., and Alcorn K. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb J 2 1 (2004) 9
44. Eikelboom J.W., Bird R., Blythe D., Coyle L., Gan E., Harvey M., et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 14 8 (2003) 713-717
45. Raivio P., Suojaranta-Ylinen R., and Kuitunen A.H. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 80 1 (2005) 66-71
46. Khan A.Z., Parry J.M., Crowley W.F., McAllen K., Davis A.T., Bonnell B.W., et al. Recombinant factor VIIa for the treatment of severe postoperative and traumatic hemorrhage. Am J Surg 189 3 (2005) 331-334
47. Bishop C.V., Renwick W.E., Hogan C., Haeusler M., Tuckfield A., and Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 81 3 (2006) 875-879
48. Clark A.D., Gordon W.C., Walker I.D., and Tait R.C. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 86 2 (2004) 120-124
49. Edmunds Jr. L.H., and Colman R.W. Thrombin during cardiopulmonary bypass. Ann Thorac Surg 82 6 (2006) 2315-2322
50. Naik V.N., Mazer C.D., Latter D.A., Teitel J.M., and Hare G.M. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth 50 6 (2003) 599-602
51. Kenet G., Walden R., Eldad A., and Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354 9193 (1999) 1879
52. Levy J.H., Fingerhut A., Brott T., Langbakke I.H., Erhardtsen E., and Porte R.J. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 46 6 (2006) 919-933
53. Boffard K.D., Riou B., Warren B., Choong P.I., Rizoli S., Rossaint R., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59 1 (2005) 8-15 [discussion 15-18]
54. Shander A., Goodnough L.T., Ratko T., Matuszewski K.A., Cohn S., Diringer M., et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharma Ther 30 (2005) 644-658
55. Goodnough L.T., Lublin D.M., Zhang L., Despotis G., and Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 44 9 (2004) 1325-1331
56. Roberts H.R. Recombinant factor VIIa: a general hemostatic agent?. Yes. J Thromb Haemost 2 10 (2004) 1691-1694
57. Brown P., Brunnhuber K., Chalkidou K., Chalmers I., Clarke M., Fenton M., et al. How to formulate research recommendations. BMJ 333 7572 (2006) 804-806